An update from the Foundation for Women's Cancer and Society of Gynecologic Oncology
Hear from Dr. Anil Sood, Foundation for Women's Cancer Research Chairman, and Carol Brown, 2014 Society of Gynecologic Oncology Program Chair, about research of interest to women and the public presented at the 2014 SGO Annual Meeting on Women's Cancer. (https://www.youtube.com/watch?v=KKB63TGlOcQ&feature=youtu.be)
Dual Checkpoint Inhibition Increases Response Rates, Adverse Effects in Melanoma
April 19th 2024Patients with high-risk resectable melanoma treated with ipilimumab plus nivolumab had increased response rates compared with anti-PD1 monotherapy, though it was also associated with increased immune-related adverse effects.